Truist analyst Danielle Brill raised the firm’s price target on Biogen (BIIB) to $193 from $190 and keeps a Hold rating on the shares after its Q4 results and guiance.. While FY26 revenue and EPS guidance were modestly above the firm’s prior estimates, the broader concerns regarding the company’s forward revenue growth trajectory remain unchanged, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $230 from $220 at Canaccord
- Biogen price target raised to $177 from $157 at Piper Sandler
- Biogen price target raised to $246 from $185 at Guggenheim
- Biogen, Eisai say BLA for Leqembi accepted for Priority Review by NMPA of China
- Biogen price target raised to $201 from $191 at Bernstein